- No file added yet -
A systematic review and network meta - analysis of pharmacological therapies used for patients with advanced Parkinson's disease (2014)
poster
posted on 2020-03-01, 16:17 authored by Shijie RenShijie Ren, Katy Cooper, James CooperJames Cooper, Helen SmithHelen Smith, Soraya ShaikhParkinson’s disease affects about 110,000 people in the UK and 1.25 million people in Europe.1 Current options for management of advanced Parkinson’s disease include:
• Increased dose or frequency of immediate-release levodopa (IR LD)
• Supplemental controlled-release levodopa (CR LD)
• Adjunctive therapies with levodopa, including dopamine agonists, monoamine oxidase-B inhibitors (MAO-BIs), and catechol-O-methyl transferase inhibitors (COMTIs) A new modified release form of levodopa (IPX066) is in development.
History
Ethics
- There is no personal data or any that requires ethical approval
Policy
- The data complies with the institution and funders' policies on access and sharing
Sharing and access restrictions
- The data can be shared openly
Data description
- The file formats are open or commonly used
Methodology, headings and units
- Headings and units are explained in the files
